Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 10282

1.

Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer.

Ferreira EN, Brianese RC, de Almeida RVB, Drummond RD, de Souza JE, da Silva IT, de Souza SJ, Carraro DM.

Transl Oncol. 2019 Aug 13;12(11):1453-1460. doi: 10.1016/j.tranon.2019.07.016. [Epub ahead of print]

2.

BRCA mutation frequency and clinical features of ovarian cancer patients: A report from a Chinese study group.

Bu H, Chen J, Li Q, Hou J, Wei Y, Yang X, Ma Y, He H, Zhang Y, Kong B.

J Obstet Gynaecol Res. 2019 Aug 14. doi: 10.1111/jog.14090. [Epub ahead of print]

PMID:
31411802
3.

An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies.

Cao J, Chen L, Li H, Chen H, Yao J, Mu S, Liu W, Zhang P, Cheng Y, Liu B, Hu Z, Chen D, Kang H, Hu J, Wang A, Wang W, Yao M, Chrin G, Wang X, Zhao W, Li L, Xu L, Guo W, Jia J, Chen J, Wang K, Li G, Shi W.

Oncologist. 2019 Aug 13. pii: theoncologist.2019-0236. doi: 10.1634/theoncologist.2019-0236. [Epub ahead of print]

PMID:
31409745
4.

The indenoisoquinoline TOP1 inhibitors selectively target homologous recombination deficient- and Schlafen 11-positive cancer cells and synergize with olaparib.

Marzi L, Szabova L, Gordon M, Weaver Ohler Z, Sharan SK, Beshiri ML, Etemadi M, Murai J, Kelly K, Pommier Y.

Clin Cancer Res. 2019 Aug 13. pii: clincanres.0419.2019. doi: 10.1158/1078-0432.CCR-19-0419. [Epub ahead of print]

PMID:
31409613
5.

Contribution of Massive Parallel Sequencing to Diagnosis of Hereditary Ovarian Cancer in the Czech Republic.

Soukupová J, Lhotová K, Zemánková P, Vočka M, Janatová M, Stolařová L, Borecká M, Kleiblová P, Macháčková E, Foretová L, Koudová M, Lhota F, Tavandzis S, Zikán M, Stránecký V, Veselá K, Panczak A, Kotlas J, Kleibl Z.

Klin Onkol. 2019 Summer;32(Supplementum2):72-78. doi: 10.14735/amko2019S72.

PMID:
31409082
6.

Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants.

Machackova E, Claes K, Mikova M, Házová J, Sťahlová EH, Vasickova P, Trbusek M, Navrátilová M, Svoboda M, Foretová L.

Klin Onkol. 2019 Summer;32(Supplementum2):51-71. doi: 10.14735/amko2019S51.

PMID:
31409081
7.

Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.

Kleiblová P, Stolařová L, Křížová K, Lhota F, Hojný J, Zemánková P, Havránek O, Vočka M, Černá M, Lhotová K, Borecká M, Janatová M, Soukupová J, Ševčík J, Zimovjanová M, Kotlas J, Panczak A, Veselá K, Červenková J, Schneiderová M, Burócziová M, Burdová K, Stránecký V, Foretová L, Macháčková E, Tavandzis S, Kmoch S, Macůrek L, Kleibl Z.

Klin Onkol. 2019 Summer;32(Supplementum2):36-50. doi: 10.14735/amko2019S36.

PMID:
31409080
8.

Effectiveness of Neoadjuvant Therapy with Platinum-Based Agents for Patients with BRCA1 and BRCA2 Germline Mutations - A Retrospective Analysis of Breast Cancer Patients Treated at MMCI Brno.

Holánek M, Bílek O, Nenutil R, Kazda T, Selingerová I, Zvaríková M, Palácová M, Krásenská M, Vyzula R, Petráková K.

Klin Onkol. 2019 Summer;32(Supplementum2):31-35. doi: 10.14735/amko2019S31.

PMID:
31409079
9.

Breast Cancer in BRCA1/2 Mutation Carriers - Do We Treat It Differently? Focus on Systemic Therapy for BRCA1/2 Associated Breast Cancer.

Palácová M.

Klin Onkol. 2019 Summer;32(Supplementum2):24-30. doi: 10.14735/amko2019S24.

PMID:
31409078
10.

Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.

Foretová L, Navrátilová M, Svoboda M, Vašíčková P, Sťahlová EH, Házová J, Kleiblová P, Kleibl Z, Macháčková E, Palácová M, Petráková K.

Klin Onkol. 2019 Summer;32(Supplementum2):6-13. doi: 10.14735/amko2019S6.

PMID:
31409076
11.

Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study.

West AH, Knollman H, Dugan J, Hedeker D, Handorf EA, Nielsen SM, Bealin LC, Goldblatt LG, Willems H, Daly MB, Afghahi A, Olopade OI, Hulick PJ, Shagisultanova E, Huo D, Obeid E, Churpek JE.

Cancer Med. 2019 Aug 12. doi: 10.1002/cam4.2471. [Epub ahead of print]

12.

BRCA1 and BRCA2 Gene Expression: Diurnal Variability and Influence of Shift Work.

Bracci M, Ciarapica V, Zabaleta ME, Tartaglione MF, Pirozzi S, Giuliani L, Piva F, Valentino M, Ledda C, Rapisarda V, Stevens RG, Santarelli L.

Cancers (Basel). 2019 Aug 9;11(8). pii: E1146. doi: 10.3390/cancers11081146.

13.

The Genetic Education for Men (GEM) Trial: Development of Web-Based Education for Untested Men in BRCA1/2-Positive Families.

Peshkin BN, Ladd MK, Isaacs C, Segal H, Jacobs A, Taylor KL, Graves KD, O'Neill SC, Schwartz MD.

J Cancer Educ. 2019 Aug 11. doi: 10.1007/s13187-019-01599-y. [Epub ahead of print]

PMID:
31402434
14.

Potentially actionable FGFR2 high-level amplification in thymic sebaceous carcinoma.

Porubsky S, Jessup P, Kee D, Sharma R, Ochi A, Xu H, Froelich JJ, Nott L, Scott C, Awad R, Moldovan C, Hardikar AA, Bohnenberger H, Küffer S, Ströbel P, Marx A.

Virchows Arch. 2019 Aug 10. doi: 10.1007/s00428-019-02644-3. [Epub ahead of print]

PMID:
31401665
15.

Regulation of the Germinal Center Reaction and Somatic Hypermutation Dynamics by Homologous Recombination.

Hirth G, Svensson CM, Böttcher K, Ullrich S, Figge MT, Jungnickel B.

J Immunol. 2019 Aug 9. pii: ji1900483. doi: 10.4049/jimmunol.1900483. [Epub ahead of print]

PMID:
31399517
16.

Computational analysis of high-risk SNPs in human CHK2 gene responsible for hereditary breast cancer: A functional and structural impact.

Badgujar NV, Tarapara BV, Shah FD.

PLoS One. 2019 Aug 9;14(8):e0220711. doi: 10.1371/journal.pone.0220711. eCollection 2019.

17.

BRCA2 loss-of-function germline mutations are associated with esophageal squamous cell carcinoma risk in Chinese.

Ko JM, Ning L, Zhao XK, Chai AW, Lei LC, Choi SSA, Tao L, Law S, Kwong A, Lee NP, Chan KT, Lo A, Song X, Chen PN, Chang YL, Wang LD, Lung ML.

Int J Cancer. 2019 Aug 9. doi: 10.1002/ijc.32619. [Epub ahead of print]

PMID:
31396961
18.

Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive women.

Sepahi I, Faust U, Sturm M, Bosse K, Kehrer M, Heinrich T, Grundman-Hauser K, Bauer P, Ossowski S, Susak H, Varon R, Schröck E, Niederacher D, Auber B, Sutter C, Arnold N, Hahnen E, Dworniczak B, Wang-Gorke S, Gehrig A, Weber BHF, Engel C, Lemke JR, Hartkopf A, Nguyen HP, Riess O, Schroeder C.

BMC Cancer. 2019 Aug 8;19(1):787. doi: 10.1186/s12885-019-5946-0.

19.

The budgetary impact of genetic testing for hereditary breast cancer for the statutory health insurance.

Neusser S, Lux B, Barth C, Pahmeier K, Rhiem K, Schmutzler R, Engel C, Wasem J, Neumann A.

Curr Med Res Opin. 2019 Aug 8:1. doi: 10.1080/03007995.2019.1654689. [Epub ahead of print]

PMID:
31394049
20.

Celebrity Influence Affecting Public Interest in Plastic Surgery Procedures: Google Trends Analysis.

Tijerina JD, Morrison SD, Nolan IT, Parham MJ, Richardson MT, Nazerali R.

Aesthetic Plast Surg. 2019 Aug 7. doi: 10.1007/s00266-019-01466-7. [Epub ahead of print]

PMID:
31392394

Supplemental Content

Loading ...
Support Center